HC Wainwright Predicts Stronger Earnings for Pharming Group

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Equities researchers at HC Wainwright upped their FY2026 earnings estimates for shares of Pharming Group in a research report issued to clients and investors on Thursday, November 6th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of $0.67 for the year, up from their prior forecast of $0.60. The consensus estimate for Pharming Group’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Pharming Group’s FY2027 earnings at $1.06 EPS.

Several other research analysts have also issued reports on PHAR. Zacks Research lowered Pharming Group from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 30th. Weiss Ratings raised Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Saturday, October 25th. Three research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Pharming Group has a consensus rating of “Moderate Buy” and an average price target of $30.00.

Pharming Group Trading Up 4.6%

Shares of NASDAQ:PHAR traded up $0.68 during mid-day trading on Friday, reaching $15.38. 15,940 shares of the company’s stock were exchanged, compared to its average volume of 7,918. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.07 and a current ratio of 2.79. Pharming Group has a twelve month low of $7.31 and a twelve month high of $17.08. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -124.31 and a beta of 0.03. The business’s fifty day moving average price is $14.29 and its 200-day moving average price is $11.95.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, November 6th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.05. The firm had revenue of $97.30 million for the quarter, compared to analyst estimates of $98.22 million. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. Pharming Group has set its FY 2025 guidance at EPS.

Institutional Trading of Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. EverSource Wealth Advisors LLC acquired a new position in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,979 shares of the company’s stock, valued at approximately $32,000. Institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.